CRBU May 2024 7.500 put
| Previous close | 2.3900 |
| Open | 2.3900 |
| Bid | 2.4500 |
| Ask | 5.4000 |
| Strike | 7.50 |
| Expiry date | 2024-05-17 |
| Day's range | 2.3900 - 2.3900 |
| Contract range | N/A |
| Volume | |
| Open interest | 11 |
GlobeNewswireCaribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences: 2024 RBC Capital Markets Global Healthcare Conference, New York, NYMay 14, 2024, fireside chat at 3:35 pm EDTWebcast BofA Securities 2024 Health Care Conference, Las Vegas, NVMay 15, 2024, corporate presentation at 3:40 pm PDTWebcast For more informa
- GlobeNewswire
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts have been accepted for poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 31-June 4, 2024 in Chicago, Illinois. The ANTLER poster will provide initial dose expansion data. Details of the poster presentation are as follows: Title: A CRI
- GlobeNewswire
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
BERKELEY, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an abstract on the efficient use of Cas12a chRDNA genome-editing technology for in vivo hepatic gene disruption has been accepted for an oral presentation at the 27th annual meeting of the American Society of Gene and Cell Therapy (ASGCT), which is being held May 7-11, 2024, in Baltimore, Maryland. Details of the
